|
Related Companies
|
[]
|
||||||||
|
Related Funds
|
[]
|
||||||||
|
|
|||||||||
|
English
|
|||||||||
|
oda_MaterialEventDisclosureGeneralAbstract|
|
|
||||||||
|
oda_UpdateAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
-
|
|||||||
|
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_AnnouncementContentSection|
|
|
||||||||
|
oda_ExplanationSection|
|
|
||||||||
|
oda_ExplanationTextBlock|
|
Our Board of Directors, which has been convened today in respect of the board of directors' decision dated April 28, 2021 of our joint venture Eczacıbaşı-Monrol Nükleer Ürünler Sanayi ve Ticaret A.Ş., of which our company has 81% of the shares, to increase its current capital from TL 17,500,000 to TL 67,500,000 by increasing TL 50,000,000, has resolved that;
- Our company shall participate in the capital increase in cash and fully by undertaking by purchasing 40,500,000 shares, each worth 1 Turkish Lira, in return for TL 40,500,000 corresponding to our share from the increased capital of TL 50,000,000;
- 25% of TL 40,500,000 which falls onto our share within the amount to be increased in cash shall be paid prior to the registration of the capital increase, and the remaining 75% shall be paid in cash after the registration of the capital increase and in any case within 24 months, at the latest.
This statement has been translated into English for informational purposes. In case of a discrepancy between the Turkish and the English versions of this disclosure statement, the Turkish version shall prevail.
|
||||||||